| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -3.8 | -7.7 |
| EPS (diluted, $ a share) | $-0.06 | $-0.13 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ALDX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Aldeyra Therapeutics, Inc.: key numbers
- Share price
- $0.6696Close, Nov 16
- Market cap
- $40.4M
- Shares outstanding
- 60.36MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Aldeyra Therapeutics, Inc.
All →Aldeyra Therapeutics Director Richard Douglas Buys $129K of Stock
Richard Douglas, Director, bought 200,000 shares of Aldeyra Therapeutics, Inc. at $0.6445 a share, worth $129K in total on Nov 11, 2026. Shares held after the trade: 395,000 (+102.6%).
- Value
- $129K
- Shares
- 200,000
- Price
- $0.6445
- Role
- Director
- Holding change
- +102.6%
- Trade date
- Nov 11, 2026
Aldeyra Therapeutics Business Update
Aldeyra Therapeutics has requested that the FDA transfer the review jurisdiction of its ADX-2191 IND for primary vitreoretinal lymphoma from the Division of Ophthalmology to the Division of Hematologic Malignancies 2. In connection with this request, the company has withdrawn its previously agreed-upon Special Protocol Assessment (SPA) protocol, creating uncertainty and potential delays in the clinical development timeline for the candidate.
- Counterparty
- FDA
Aldeyra Therapeutics Investor Presentation
Aldeyra Therapeutics announced its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA appealing a prior Complete Response Letter for reproxalap in dry eye disease. The company also extended its projected cash runway into 2029 and filed a formal supplemental presentation detailing the regulatory update and upcoming meeting with the FDA's Office of New Drugs.
- Counterparty
- FDA